Pörssitiedote26.6.2024 klo 9.00Redwood Pharma provides a new update regarding divestment of company assets
Lehdistötiedote12.6.2024 klo 10.00Redwood Pharma provides an update on the process for divesting the company's assets
Lehdistötiedote8.5.2024 klo 6.30Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle
Lehdistötiedote7.5.2024 klo 6.30Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements
Lehdistötiedote28.2.2024 klo 7.30Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle
Lehdistötiedote19.12.2023 klo 7.00Redwood Pharma to participate in the JP Morgan Healthcare Conference
Pörssitiedote30.11.2023 klo 7.30Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)
Lehdistötiedote22.11.2023 klo 7.30Redwood Pharma to participate in the NLS Days partner conference in Copenhagen
Lehdistötiedote19.10.2023 klo 9.15Redwood Pharma to participate in the BIO-Europe partnering conference in Munich
Pörssitiedote31.5.2023 klo 21.10Redwood Pharma presents positive results from a clinical study with RP501 against dry eye
Lehdistötiedote17.3.2023 klo 12.00Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye
Lehdistötiedote24.1.2023 klo 7.30Redwood Pharma takes important steps towards the commercial production of its dry eye product
Pörssitiedote15.12.2022 klo 16.00Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501
Lehdistötiedote19.10.2022 klo 13.18Interview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm
Lehdistötiedote14.10.2022 klo 6.30Redwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022
Lehdistötiedote3.10.2022 klo 13.42Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45